SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Both organisations enter into a long- term collaboration to expand patient access in India
The drug will target specific genetic mutations prevalent in certain types of cancers
This agreement paves the way for the introduction of YESAFILI into the Canadian market
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Subscribe To Our Newsletter & Stay Updated
